The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis

Hepatology

Volumn 64, Issue 1, 2016, Pages 200-208

  Bajaj, Jasmohan S ^a   Reddy, K Rajender ^b   Tandon, Puneeta ^c   Wong, Florence ^d   Kamath, Patrick S ^e   Garcia Tsao, Guadalupe ^f   Maliakkal, Benedict ^g   Biggins, Scott W ^h   Thuluvath, Paul J ⁱ   Fallon, Michael B ^j   Subramanian, Ram M ^k   Vargas, Hugo ^l   Thacker, Leroy R ^a   O'Leary, Jacqueline G ^m  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MAYO CLINIC   (United States)

^f YALE UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ MERCY MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k EMORY UNIVERSITY   (United States)

^l MAYO CLINIC   (United States)

^m BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; RIFAXIMIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYDROTHORAX; INFECTION; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; NORTH AMERICAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

EID: 84976509929     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28414     Document Type: Article

References (43)

1. Fontanarosa PB, McNutt RA. Revisiting hospital readmissions. JAMA 2013;309:398-400.
2. Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med 2000;160:1074-1081.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009;136:1134-1144.
4. Kanwal F, Volk M, Singal A, Angeli P, Talwalkar J. Improving quality of health care for patients with cirrhosis. Gastroenterology 2014;147:1204-1207.
5. Picker D, Heard K, Bailey TC, Martin NR, LaRossa GN, Kollef MH. The number of discharge medications predicts thirty-day hospital readmission: a cohort study. BMC Health Serv Res 2015;15:282.
6. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 2012;107:247-252.
7. Singal AG, Rahimi RS, Clark C, Ma Y, Cuthbert JA, Rockey DC, et al. An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol 2013;11:1335-1341.
8. Berman K, Tandra S, Forssell K, Vuppalanchi R, Burton JR Jr, Nguyen J, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254-259.
9. Ganesh S, Rogal SS, Yadav D, Humar A, Behari J. Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One 2013;8:e55140.
10. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the Study of End-Stage Liver Disease (NACSELD) experience. Hepatology 2012;56:2328-2335.
11. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
13. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. Hoboken, NJ: John Wiley and Sons; 2013.
14. Wong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013;145:1280-1288.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
16. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-735.
17. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014;60:250-256.
18. Wong EL, Cheung AW, Leung MC, Yam CH, Chan FW, Wong FY, et al. Unplanned readmission rates, length of hospital stay, mortality, and medical costs of ten common medical conditions: a retrospective analysis of Hong Kong hospital data. BMC Health Serv Res 2011;11:149.
19. Centers for Medicare & Medicaid Services. Hospital-acquired conditions (present on admission indicator). https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index.html?redirect=/HospitalAcqCond/01_Overview.asp.
20. Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012;61:1219-1225.
21. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8:979-985.
22. Kanwal F. Decreasing mortality in patients hospitalized with cirrhosis. Gastroenterology 2015;148:897-900.
23. Schmidt ML, Barritt AS, Orman ES, Hayashi PH. Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010. Gastroenterology 2015;148:967-977.
24. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012;56(Suppl. 1):S1-S12.
25. Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN). http://www.cdc.gov/nhsn/cms/index.html.
26. O'Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:753-759.
27. Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014;307:G951-G957.
28. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009;54:2312-2317.
29. Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 2015;35:362-369.
30. Fernandez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551-1561.
31. Saab S. Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med;8:165-173.
32. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-2340.
33. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2010;9:181-183.
34. Bajaj JS, Riggio O, Allampati S, Prakash R, Gioia S, Onori E, et al. Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol 2013;11:1511-1516.
35. Callahan KE, Lovato JF, Miller ME, Easterling D, Snitz B, Williamson JD. Associations between mild cognitive impairment and hospitalization and readmission. J Am Geriatr Soc 2015;63:1880-1885.
36. Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology 2015;62:584-590.
37. Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011;306:1688-1698.
38. Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 2013;59:257-264.
39. Vaduganathan M, Bonow RO, Gheorghiade M. Thirty-day readmissions: the clock is ticking. JAMA 2013;309:345-346.
40. Ge PS, Runyon BA. Care coordination for patients with cirrhosis: a “win-win” solution for patients, caregivers, providers, and healthcare expenditures. J Hepatol 2013;59:203-204.
41. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation 2012;126:501-506.
42. Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol 2014;12:692-698.
43. O'Connor NR, Moyer ME, Behta M, Casarett DJ. The impact of inpatient palliative care consultations on 30-day hospital readmissions. J Palliat Med 2015;18:956-961.